Navigation Links
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Date:3/12/2009

data evaluating the safety and performance of a bioabsorbable drug eluting coronary stent out to two years. Abbott's bioabsorbable everolimus eluting coronary device is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbott's bioabsorbable stent is designed to restore blood flow by propping a clogged vessel open, and to provide support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable device is designed to be slowly metabolized by the body and completely absorbed over time.

"Abbott has consistently been at the forefront of advances in interventional cardiology - from the early days of angioplasty to our continued success with bare metal stents and the market-leading XIENCE V drug eluting stent. Our bioabsorbable device is another example of scientific innovation leading to an interventional breakthrough," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Today's data publication in The Lancet confirms the promise our bioabsorbable device holds as a vasorestorative therapy for patients with coronary artery disease."

Abbott will begin enrolling patients in the second phase of its international ABSORB clinical trial in the first half of 2009.

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label), two-phase study designed to enroll approximately 110 patients in Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days, six, nine and 18 months, and one and two years, with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioabsorbable drug eluting stent, including successful deployment of the sten
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
4. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
7. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
8. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
9. SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa
10. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
11. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 01, 2015 Research and Markets ... the "US ACO IT Spending Outlook 2018" ... that number of lives covered by ACO would grow ... this report, the ACO IT spending has been studied ... on software and spending on services. Our research provides ...
(Date:5/1/2015)... May 1, 2015  Thoratec Corporation (NASDAQ: THOR ), ... support and restore failing hearts, announced today that Marta ... of President, International. This new Europe ... outside of North America , including ... Latin America , and reports directly to ...
(Date:5/1/2015)... Corporation (CYTR), a biopharmaceutical research and development company ... the three months ended March 31, 2015, and ... milestones for its clinical development programs. ... of 2015, including the announcement of encouraging data ... with soft tissue sarcoma, and positive interim data ...
Breaking Medicine Technology:United States ACO IT Spending Outlook 2014-2018 2Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11
... stimulants combined provide greater improvement in symptoms ... Addrenex Pharmaceuticals, Inc. today announced positive results ... Clonicel demonstrating that the combination of Clonicel ... in attention deficit hyperactivity disorder (ADHD) symptoms ...
... After a review of several vendors, the University ... selected the services of Velos and its flagship product, ... implemented at UCLA,s Jonsson Comprehensive Cancer Center and an ... Plans are in place to deploy the system in ...
Cached Medicine Technology:Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication 2University of California Los Angeles Selects Velos eResearch 2University of California Los Angeles Selects Velos eResearch 3University of California Los Angeles Selects Velos eResearch 4University of California Los Angeles Selects Velos eResearch 5University of California Los Angeles Selects Velos eResearch 6
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch as part of ... technology products available to consumers. Scott Steinberg, a technology expert ... with viewers how to protect their private information. , A ... and even more so online. It helps everyone stay connected ... world. In terms of work, the internet makes things more ...
(Date:5/3/2015)... MA (PRWEB) May 03, 2015 SpineFrontier, ... clearance from the FDA to produce and market their ... device can be used in outpatient settings and is ... The alternate posterior approach has been extensively researched and ... 510k approval to use this approach in conjunction with ...
(Date:5/2/2015)... As one of only 30 Illinois companies ... Health Achievement and Recognition Program (SHARP) certification, Essentra ... the Illinois Department of Labor to host this special ... certification by the Occupational Safety and Health Administration’s (“OSHA”) ... to meet or exceed all of the necessary regulations ...
(Date:5/2/2015)... “ ActOn ” was featured on NewsWatch ... at the latest and coolest applications on the market for ... and technology expert, conducted the app review and shared with ... organizations to make a difference. , In this material world, ... that aren’t about money, which is why those things should ...
(Date:5/2/2015)... FL (PRWEB) May 02, 2015 We ... selected The Delray Recovery Center as one of the ... is known in the addiction treatment field for their ... members to innovate and to continue their educational efforts. ... positive workplace environment, never forgetting their purpose – to ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2
... screens, researchers say , TUESDAY, June 2 (HealthDay News) -- ... more types of cancer than previously thought, a new study ... successfully used for early detection of colorectal cancer, researchers at ... also good at finding other gastrointestinal cancers, such as those ...
... that a noninvasive screening test can detect not only colorectal ... including pancreas, stomach, biliary and esophageal cancers. This is one ... Digestive Disease Week 2009 in Chicago, May 30 June ... in four cancer deaths. While high cure rates can be ...
... New York, NY 2 June 2009 -- PharmaPendium ... clinical and post-marketing drug information, has significantly expanded its ... documents with the launch of the FDA Classic Collection. ... up to and including those issued in 1991 ...
... to use a new, cutting edge diagnostic technology to fight ... , WOBURN, Mass., and VEDBAEK, Denmark, June 2 ... Savannah, Georgia has implemented AdvanDx,s PNA FISH(R) tests to identify ... to help their physicians, pharmacists and nurses improve care and ...
... Pa., June 2 Globus Medical, Inc., the largest privately ... launch of the COALITION(TM) ACDF Spacer System. COALITION(TM) is ... biomechanical strength of a traditional ACDF with less disruption of ... , The COALITION(TM) technology combines a PEEK interbody spacer with ...
... Del., June 2 Two studies from ... gastroesophageal reflux disease (GERD) patients treated with NEXIUM(R) (esomeprazole ... heartburn and GERD-related sleep disturbances compared with patients taking ... for the treatment of heartburn and other symptoms associated ...
Cached Medicine News:Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 3Health News:Elsevier's PharmaPendium introduces the FDA Classic Collection 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:Globus Medical Announces Launch of COALITION(TM) ACDF Spacer System 2Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 2Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 3Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 4Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 5
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
Shandon Paraffin Block Cartons...
... embedment block cataloging and ... system incorporates the necessary ... protection, simplified cataloging, reduction ... facilitation of retrieval. All ...
The Modular Storage Drawers provide permanent storage and identification of up to 165 embedding rings or 250 cassettes per drawer....
Medicine Products: